Je was op zoek naar: knæalloplastik (Deens - Engels)

efter elektiv knæalloplastik
patients following elective knee replacement surgery

2 500 patienter, der gennemgik knæalloplastik.
in all of the studies, the effectiveness was measured by looking at the number of patients who either had blood clots in the veins or in the lungs, or who died of any cause during the treatment period.

2. 531 patienter, der fik foretaget knæalloplastik
2,531 patients undergoing total replacement surgery

forebyggelse af vte: elektiv hofte- eller knæalloplastik
prevention of vte: elective hip or knee replacement surgery

primær forebyggelse af vte efter hofte-eller knæalloplastik
primary vte prevention after hip or knee replacement surgery

forebyggelse af vte (vtep): elektiv hofte- eller knæalloplastik
prevention of vte (vtep): elective hip or knee replacement surgery

forebyggelse af venøs tromboemboli (vte) hos patienter efter elektiv knæalloplastik:
prevention of venous thromboembolism (vte) in patients following elective knee replacement surgery:

doseringsanbefalinger før og efter invasive indgreb og kirurgi ud over elektiv hofte- eller knæalloplastik.
dosing recommendations before and after invasive procedures and surgical intervention other than elective hip or knee replacement surgery

primær forebyggelse af venøs tromboemboli hos voksne patienter ved elektiv total hofte - eller knæalloplastik.
primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

primær forebyggelse af venøs tromboemboli hos voksne patienter efter elektiv total hofte- eller knæalloplastik.
primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

patienter, som gennemgår hofte - eller knæalloplastik, har højere risiko for at danne blodpropper i venerne.
patients undergoing hip or knee replacement surgery are at a high risk of forming blood clots in the veins.

behandlingen bør fortsætte i fem uger hos patienter, som har gennemgået hoftealloplastik, og i to uger hos patienter, som har gennemgået knæalloplastik.
treatment should continue for five weeks in patients who have had hip replacement surgery, and for two weeks in patients who have had knee replacement surgery.

primær forebyggelse af venøs tromboemboli (vte) hos voksne patienter efter elektiv total hofte- eller knæalloplastik.
primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

iagttaget ved forbyggelse af venøs tromboemboli (vte) hos voksne patienter, som gennemgår elektiv hofte- eller knæalloplastik.
a: observed in prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery

efter knæalloplastik bør behandlingen påbegyndes 1-4 timer efter afsluttet operation med én enkel kapsel oralt.efterfølgende gives 2 kapsler dagligt i 10 dage i alt.
after knee replacement surgery treatment should be initiated orally within 1 ­ 4 hours of completed surgery with a single capsule and continuing with 2 capsules once daily thereafter for a total of 10 days.

det kliniske program for apixaban blev udformet til at påvise apixabans virkning og sikkerhed i forebyggelsen af vte i et bredt udvalg af voksne patienter, som fik elektiv hofte- og knæalloplastik.
the apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of vte in a broad range of adult patients undergoing elective hip or knee replacement.

det er ikke relevant at anvende pradaxa til indikationen primær forebyggelse af venøs tromboemboli (vte) efter elektiv hofte-eller knæalloplastik i den pædiatriske population.
there is no relevant use of pradaxa in the paediatric population for the indication of primary prevention of venous thromboembolic events in patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

til forebyggelse af vte ved elektiv hofte- eller knæalloplastik, til forebyggelse af apopleksi og systemisk emboli hos patienter med nvaf og til forebyggelse af recidiverende dvt og le: apixaban bør anvendes med forsigtighed;
for the prevention of vte in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with nvaf and for the prevention of recurrent dvt and pe, apixaban should be used with caution;

udvalget for humanmedicinske lægemidler (chmp) konkluderede, at fordelene ved pradaxa er større end risiciene ved primær forebyggelse af venøse tromboemboliske hændelser hos voksne patienter, der har fået elektiv total hoftealloplastik (hofteledsudskiftning) eller total knæalloplastik (knæledsudskiftning).
the committee for medicinal products for human use (chmp) decided that pradaxa’ s benefits are greater than its risks for primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.